SCHEMBL629401

SCHEMBL629401

CCOC(=O)c1ccncc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
NUDT1 P36639 1/20 0.49
TP53 P04637 1/20 0.46
CASP1 P29466 1/20 0.46
CDC7 O00311 1/20 0.46
DBF4 Q9UBU7 1/20 0.46
HSD17B10 Q99714 2/20 0.44
GCGR P47871 1/20 0.44
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM5A P29375 1/20 0.44
KDM5B Q9UGL1 1/20 0.44
DCTPP1 Q9H773 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6553907 0.87 TSHR (0.50) TSHRNUDT1TP53CASP1CDC7
Bromide SCHEMBL28948302 0.85 TSHR (0.49) TSHRNUDT1TP53CASP1CDC7
SCHEMBL3515887 0.84 TSHR (0.60) TSHRNUDT1TP53CASP1CDC7
SCHEMBL29837473 0.84 TSHR (0.60) TSHRNUDT1TP53CASP1CDC7
SCHEMBL277304 0.83 TSHR (0.53) TSHRNUDT1TP53CASP1CDC7
SCHEMBL31043446 0.81 GAA (0.40) NUDT1TP53CASP1NPSR1ALDH1A1
SCHEMBL12447815 0.81 TSHR (0.52) TSHRNUDT1TP53CASP1CDC7
SCHEMBL2568123 0.81 CA12 (0.56) TSHRNUDT1TP53CASP1CDC7
SCHEMBL13758656 0.81 TSHR (0.52) TSHRNUDT1TP53CASP1CDC7
SCHEMBL359044 0.81 KDM4E (0.64) TSHRCASP1HSD17B10POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12215107-B1 Pyrazino[1′,2′:1,5]pyrazolo[4,3-c] [2,6] naphthyridine compounds as CK2 inhibitors King Faisal University (SA) 2025-02-04 US disclosed
CN-117263934-A Preparation method of 5H-benzo [ c ] [1,6] naphthyridine-6-ketone derivative 上海凌凯医药科技有限公司 2023-12-22 CN disclosed
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-06-22 US disclosed
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-06-22 US disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
WO-2023025277-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2023-03-02 WO disclosed
WO-2009097014-A2 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-08-06 WO disclosed
EP-2061765-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS Cylene Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME ATG7, SQSTM1, BECN1 TSHR 3602/4885NUDT1 4353/4885TP53 180/4885
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS PACSIN2, CKS1B, CSNK1A1 TSHR 3445/4885NUDT1 3860/4885TP53 625/4885
US-12215107-B1 Pyrazino[1′,2′:1,5]pyrazolo[4,3-c] [2,6] naphthyridine compounds as CK2 inhibitors CSNK2A3, CKS2, CDK2 TSHR 3490/4885NUDT1 3514/4885TP53 143/4885
US-11780821-B2 Inhibitors of fibroblast activation protein FAP, FIBP, FRS2 TSHR 4609/4885NUDT1 1356/4885TP53 411/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 TSHR 4131/4885NUDT1 2665/4885TP53 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.